Anti-doping raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-01-15 and is reviewed periodically as new material appears.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
Stability of GW501516 depends on form, temperature, light exposure, and moisture. Solid reference material is typically stored frozen or refrigerated in a desiccator and protected from light. Solutions in organic solvents such as dimethyl sulfoxide are often kept frozen in aliquots to reduce freeze-thaw cycling. Aqueous solubility is low, so aqueous stock solutions can be difficult to prepare without cosolvents. Degradation may appear as changes in chromatographic purity or mass spectral signal. Stability studies are needed to establish shelf life for any specific preparation.
Quality assessment for cardarine samples usually combines identity, purity, and impurity testing. Nuclear magnetic resonance spectroscopy and mass spectrometry can confirm molecular structure, while high-performance liquid chromatography estimates purity. Certificates of analysis from testing laboratories may list these results, but they do not establish safety or legality. In the absence of approved manufacturing, products sold online may contain the wrong compound, variable amounts, or unlisted contaminants. Independent verification is therefore central to analytical work and to interpreting any reported biological activity.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human therapeutic use | No marketing authorization identified in major jurisdictions. |
| Anti-doping class | PPARδ agonist; hormone and metabolic modulators | Listed on the WADA Prohibited List. |
| Common test matrix | Urine | Also blood and tissue in research settings. |
| Typical analytical method | LC-MS/MS | Targets parent compound and metabolites. |
| Major safety signal | Tumor findings in rodents | Human relevance not established; limited human data. |
Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.
Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.
Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.
Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
In December 1975, attempting to circumvent the restrictions of the banning order, the BPC declared Biko their honorary president. After Biko and other BCM leaders were banned, a new leadership arose, led by Muntu Myeza and Sathasivian Cooper, who were considered part of the Durban Moment. Myeza and Cooper organised a BCM demonstration to mark Mozambique's independence from Portuguese colonial rule in 1975. Biko disagreed with this action, correctly predicting that the government would use it to crack down on the BCM. The government arrested around 200 BCM activists, nine of whom were brought before the Supreme Court, accused of subversion by intent. The state claimed that Black Consciousness philosophy was likely to cause "racial confrontation" and therefore threatened public safety. Biko was called as a witness for the defence; he sought to refute the state's accusations by outlining the movement's aims and development. Ultimately, the accused were convicted and imprisoned on Robben Island. In 1973, Biko had enrolled for a law degree by correspondence from the University of South Africa. He passed several exams, but had not completed the degree at his time of death. His performance on the course was poor; he was absent from several exams and failed his Practical Afrikaans module. The state security services repeatedly sought to intimidate him; he received anonymous threatening phone calls, and gun shots were fired at his house. A group of young men calling themselves 'The Cubans' began guarding him from these attacks.
A subunit vaccine is a vaccine that contains purified parts of the pathogen that are antigenic, or necessary to elicit a protective immune response. Subunit vaccine can be made from dissembled viral particles in cell culture or recombinant DNA expression, in which case it is a recombinant subunit vaccine. A "subunit" vaccine doesn't contain the whole pathogen, unlike live attenuated or inactivated vaccine, but contains only the antigenic parts such as proteins, polysaccharides or peptides. Because the vaccine doesn't contain "live" components of the pathogen, there is no risk of introducing the disease, and is safer and more stable than vaccines containing whole pathogens. Other advantages include being well-established technology and being suitable for immunocompromised individuals. Disadvantages include being relatively complex to manufacture compared to some vaccines, possibly requiring adjuvants and booster shots, and requiring time to examine which antigenic combinations may work best. The first recombinant subunit vaccine was produced in the mid-1980s to protect people from Hepatitis B. Other recombinant subunit vaccines licensed include Engerix-B (hepatitis B), Gardasil 9 (Human Papillomavirus), Flublok (influenza), Shingrix (Herpes zoster) and Nuvaxovid (Coronavirus disease 2019). After injection, antigens trigger the production of antigen-specific antibodies, which are responsible for recognising and neutralising foreign substances. Basic components of recombinant subunit vaccines include recombinant subunits, adjuvants and carriers.
== Career and research == In March 1947, de Duve joined the faculty of the medical school of the Catholic University of Leuven teaching physiological chemistry. In 1951 he became full professor. In 1960, Detlev Bronk, the then president of the Rockfeller Institute (what is now Rockefeller University) of New York City, met him at Brussels and offered him professorship and a laboratory. The rector of Leuven, afraid of entirely losing de Duve, made a compromise over dinner that de Duve would still be under part-time appointment with a relief from teaching and conducting examinations. The rector and Bronk made an agreement which would initially last for five years. The official implementation was in 1962, and de Duve simultaneously headed the research laboratories at Leuven and at Rockefeller University, dividing his time between New York and Leuven. In 1969, the Catholic University of Leuven was contentiously split into two separate universities along linguistic lines. De Duve chose to join the French-speaking side, Université catholique de Louvain. He took emeritus status at the University of Louvain in 1985 and at Rockefeller in 1988, though he continued to conduct research. Among other subjects, he studied the distribution of enzymes in rat liver cells using rate-zonal centrifugation. His work on cell fractionation provided an insight into the function of cell structures. He specialized in subcellular biochemistry and cell biology and discovered new cell organelles.
=== EC 1.10.3 With oxygen as acceptor === EC 1.10.3.1: catechol oxidase EC 1.10.3.2: laccase EC 1.10.3.3: L-ascorbate oxidase EC 1.10.3.4: o-aminophenol oxidase EC 1.10.3.5: 3-hydroxyanthranilate oxidase EC 1.10.3.6: rifamycin-B oxidase EC 1.10.3.7: Now EC 1.21.3.4, sulochrin oxidase [(+)-bisdechlorogeodin-forming] EC 1.10.3.8: Now EC 1.21.3.5, sulochrin oxidase [(-)-bisdechlorogeodin-forming] EC 1.10.3.9: photosystem II EC 1.10.3.10: Now EC 7.1.1.3, ubiquinol oxidase (H+-transporting) EC 1.10.3.11: ubiquinol oxidase (non-electrogenic) EC 1.10.3.12: Now EC 7.1.1.5, menaquinol oxidase (H+-transporting) EC 1.10.3.13: Now EC 7.1.1.4, caldariellaquinol oxidase (H+-transporting) EC 1.10.3.14: Now EC 7.1.1.7, ubiquinol oxidase (electrogenic, proton-motive force generating) EC 1.10.3.15: grixazone synthase EC 1.10.3.16: dihydrophenazinedicarboxylate synthase EC 1.10.3.17: superoxide oxidase
Sources: en.wikipedia.org
=== As a supplement === A series of studies showed that a combination of betaine and glycocyamine improves the symptoms of patients with chronic illness, including heart disease, without toxicity. Betaine can provide a methyl group to glycocyamine, via methionine, for the formation of creatine. In overall, such treatment led to less fatigue, greater strength and endurance, and an improved sense of well-being. The patients with cardiac decompensation (arteriosclerosis or rheumatic disease) and congestive heart failure had improved cardiac function. The patients gained weight (improved nitrogen balance) and saw lessened symptoms of arthritis and asthma and increased libido, and those people suffering from hypertension experienced transient reduced blood pressure. Also the studies shows the increase of glucose tolerance in both diabetic subjects and subjects without diabetes.
=== Other uses === Research into fungal dressings for the treatment of ulcers, and bed sores, using fungal mycelial filaments, is ongoing. In the past, slices of A. campestris were applied to scalds and burns in parts of Scotland.
Rete pegs (also known as rete processes, rete ridges or epidermal ridges) are the epithelial extensions that project into the underlying connective tissue in both skin and mucous membranes. In the epithelium of the mouth, the attached gingiva exhibit rete pegs, while the sulcular and junctional epithelia do not. Scar tissue lacks rete pegs and scars tend to shear off more easily than normal tissue as a result. Also known as papillae, they are downward thickenings of the epidermis between the dermal papillae.
Sources: en.wikipedia.org
Further purification of the protein from rat livers and kidneys in 1980 by Polish biochemists led by Andrzej J. Żelazowski and Jadwiga A. Szymańska indicated that the protein exists in distinct types (isoforms), each specific for cadmium, copper and mercury. These proteins were later named isoforms of type 1 and 2 (MT1 and MT2). In 1991, a team of Japanese neuroscientists found a different metallothionein in human brain that acted as growth inhibitor and linked to Alzheimer's disease. The protein became MT3. In 1994, a team led by Richard D. Palmiter of the University of Washington discovered the fourth type, MT4, from the epithelial cells of mouse and humans. The formal classification was introduced by Pierre-Alain Binz and Kägi in 1999. Due to their obscure nature and diversity, the exact biological functions of metallothioneins were difficult to study and became established only by the mid-1990s. As Vallee later remarked, it took "40 years of frustrating efforts" to understand that the proteins are responsible for several fundamental cellular activities including zinc-dependent gene activation, growth inhibition of neurones, apoptosis and regulation of oxidative stress.
set up a laboratory in the kitchen and woodshed of an old house in Washington near the area now occupied by buildings of the Department of Agriculture and there completed their researches on butter. This was the first dairy products research laboratory in Washington. Lore Rogers completed his first publications on butter. About this time he was elected to the Society of American Bacteriologists and in Washington married Beatrice Oberly, who was employed as bureau librarian. "Fishy Flavor in Butter" and "The Influence of Acidity of Cream on the Flavor of Butter" were published next. In 1909 the Dairy Research Laboratories were finally created and placed under the direction of Lore Rogers. His son, John Oberly Rogers, was born the same year. In 1911 he was selected as an official delegate representing the United States at the International Dairy Congress meeting at Stockholm. A publication on the spoiling of butter was published by the United States Department of Agriculture. By 1914 he was developing a procedure for preserving bacterial cultures by removing gas while in their frozen state. A few years later the United States Army would adopt the technique in the preparation of typhoid vaccines during World War I. In 1916 Lore Rogers became an advisory editor of the Journal of Bacteriology. A year later he was secretary of the Washington Branch of the Society of American Bacteriologists. In 1920 and 1921 he published articles on the manufacture of sweetened condensed milk and evaporated milk. In 1920 and 1922 he served as president of the American Society of Bacteriologists.
Canthaxanthin Chédiak–Higashi syndrome Chrysiasis Cross–McKusick–Breen syndrome (Cross syndrome, oculocerebral-hypopigmentation syndrome) Dermatopathia pigmentosa reticularis (dermatopathia pigmentosa reticularis hyperkeratotica et mutilans, dermatopathia pigmentosa reticularis hypohidotica et atrophica, dermatopathic pigmentosa reticularis) Dyschromatosis symmetrica hereditaria (reticulate acropigmentation of Dohi, symmetrical dyschromatosis of the extremities) Dyschromatosis universalis hereditaria Elejalde syndrome (Griscelli syndrome type 1) Eruptive hypomelanosis Familial progressive hyperpigmentation Galli–Galli disease Griscelli syndrome type 2 (partial albinism with immunodeficiency) Griscelli syndrome type 3 Hemochromatosis (bronze diabetes) Hemosiderin hyperpigmentation Hermansky–Pudlak syndrome Idiopathic guttate hypomelanosis (leukopathia symmetrica progressiva) Iron metallic discoloration Klein–Waardenburg syndrome Lead poisoning Leukoderma Melanoma-associated leukoderma Melasma (chloasma faciei, mask of pregnancy) Mukamel syndrome Necklace of Venus Nevus anemicus Nevus depigmentosus (nevus achromicus) Ocular albinism Oculocutaneous albinism Pallister–Killian syndrome Periorbital hyperpigmentation Photoleukomelanodermatitis of Kobori Phylloid hypomelanosis Piebaldism Pigmentatio reticularis faciei et colli Pityriasis alba Poikiloderma of Civatte Poikiloderma vasculare atrophicans Postinflammatory hyperpigmentation (postinflammatory hypermelanosis) Postinflammatory hypopigmentation Progressive macular hypomelanosis Quadrichrome vitiligo Reticular pigmented anomaly of the flexures (dark dot disease, Dowling–Degos' disease) Reticulate acropigmentation of Kitamura Revesz syndrome Riehl melanosis Scratch dermatitis (flagellate pigmentation from bleomycin) Segmental vitiligo Shah–Waardenburg syndrome Shiitake mushroom dermatitis (flagellate mushroom dermatitis, mushroom worker's disease, shiitake-induced toxicoderma) Tar melanosis (melanodermatitis toxica lichenoides) Tietz syndrome Titanium metallic discoloration Transient neonatal pustular melanosis (transient neonatal pustulosis, lentigines neonatorum) Trichrome vitiligo Vagabond's leukomelanoderma Vasospastic macule Vitiligo Vitiligo ponctué Vogt–Koyanagi–Harada syndrome Waardenburg syndrome Wende–Bauckus syndrome (Pegum syndrome) Woronoff's ring X-linked reticulate pigmentary disorder (familial cutaneous amyloidosis, Partington amyloidosis, Partington cutaneous amyloidosis, Partington syndrome type II, reticulate pigmentary disorder, X-linked reticulate pigmentary disorder with systemic manifestations) Yemenite deaf-blind hypopigmentation syndrome
SRIs like citalopram and paroxetine, as well as the serotonin 5-HT2A receptor antagonist ketanserin, have been found to partially block the increases in heart rate and blood pressure with MDMA. It is notable in this regard that serotonergic psychedelics such as psilocybin, which act as serotonin 5-HT2A receptor agonists, likewise have sympathomimetic effects. The NRI reboxetine and the serotonin–norepinephrine reuptake inhibitor (SNRI) duloxetine block MDMA-induced increases in heart rate and blood pressure. Conversely, bupropion, a norepinephrine–dopamine reuptake inhibitor (NDRI) with only weak dopaminergic activity, reduced MDMA-induced heart rate and circulating norepinephrine increases but did not affect MDMA-induced blood pressure increases. On the other hand, the robust NDRI methylphenidate, which has sympathomimetic effects of its own, has been found to augment the cardiovascular effects and increases in circulating norepinephrine and epinephrine levels induced by MDMA. The non-selective beta blocker pindolol blocked MDMA-induced increases in heart rate but not blood pressure. The α2-adrenergic receptor agonist clonidine did not affect the cardiovascular effects of MDMA, though it reduced blood pressure. The α1-adrenergic receptor antagonists doxazosin and prazosin blocked or reduced MDMA-induced blood pressure increases but augmented MDMA-induced heart rate and cardiac output increases. The dual α1- and β-adrenergic receptor blocker carvedilol reduced MDMA-induced heart rate and blood pressure increases.
Sources: en.wikipedia.org
No. Cardarine has not received approval for human therapeutic use in major jurisdictions. It remains an investigational compound.
It is classified as a PPARδ agonist on the WADA Prohibited List. Anti-doping laboratories can detect it and its metabolites in urine. Its use is banned in competition and usually out of competition.
Rodent studies reported increased tumor incidence at multiple sites. The human relevance remains uncertain, but the findings contributed to discontinuation of development. No long-term human cancer data are available.
LC-MS/MS is common, often after sample cleanup. The assay targets GW501516 or its metabolites.